What is the current Angiogenesis Inhibitors market size?

The Angiogenesis Inhibitors market size is approximately USD 11.4 billion as of 2022.

What is the expected growth forecast for the Angiogenesis Inhibitors market?

The market is expected to grow at a CAGR of 7.8% from 2023 to 2028.

What are the key drivers of the Angiogenesis Inhibitors market?

Increasing cancer prevalence and rising demand for targeted therapies drive the market.

What are the major challenges facing the Angiogenesis Inhibitors market?

High development costs and stringent regulatory requirements pose significant challenges.

Which regions are leading the Angiogenesis Inhibitors market?

North America and Europe are the leading regions due to high healthcare expenditure.

Who are the top companies in the Angiogenesis Inhibitors market?

Pfizer, Roche, and Novartis are among the top companies in the market.

What are the future opportunities in the Angiogenesis Inhibitors market?

Emerging markets and increasing use in ophthalmology offer future growth opportunities.

How does technology impact the Angiogenesis Inhibitors market?

Advances in nanotechnology and biomarkers improve drug delivery and efficacy.

What is the current regulatory landscape for Angiogenesis Inhibitors?

Regulatory frameworks vary by region, with the FDA and EMA playing key roles.

What is the future outlook for the Angiogenesis Inhibitors market?

The market is expected to experience steady growth due to increasing demand.

Angiogenesis Inhibitors Growth Opportunities & Strategic Forecast 2033

Angiogenesis Inhibitors by Application (Kidney Cancer, Lung Cancer, Breast Cancer, Colon Cancer, Other), by Types (Oral, Injectable, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Angiogenesis Inhibitors Market Size | CAGR 10.2 Forecast 2033

Angiogenesis Inhibitors Growth Opportunities & Strategic Forecast 2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Angiogenesis Inhibitors Market Overview

The Angiogenesis Inhibitors market refers to the industry focused on developing and marketing drugs that inhibit the formation of new blood vessels, a process known as angiogenesis. As the Angiogenesis Inhibitors market size is projected to experience significant growth, driven by increasing demand for effective cancer treatments, the growth outlook and market forecast are crucial for industry stakeholders. The industry expansion is expected to be fueled by advancements in medical research and technology, with the current market size estimated to be around $13.3 billion. The growth forecast indicates a Compound Annual Growth Rate (CAGR) of 8.5% from 2026 to 2033, driven by macro drivers such as the rising prevalence of cancer and the increasing adoption of angiogenesis inhibitors in cancer treatment.

Loading chart…

Key forces shaping the industry include technology shifts towards more targeted and effective treatments, regulations supporting the development of new drugs, and consumer behavior driving demand for innovative cancer therapies. The largest region in the Angiogenesis Inhibitors market is North America, while the fastest-growing region is expected to be Asia Pacific. As the market continues to evolve, Angiogenesis Inhibitors market size and growth outlook will be crucial for industry stakeholders to navigate the competitive landscape and capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Pfizer; Exelixis; Novartis; Takeda Pharmaceutical; Melinta Therapeutics; Cipla; Sun Pharmaceutical Industries; Bristol-Myers Squibb; Balaji Medical Services; Eli Lilly; Bayer; Sanofi; Merck & Co
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Increasing cancer prevalence and the growing need for effective treatments are driving the demand for Angiogenesis Inhibitors, thereby contributing to the growth of the Angiogenesis Inhibitors market size and its growth forecast.

Advances in biotechnology and pharmaceutical research have led to the development of innovative Angiogenesis Inhibitors, further fueling the expansion of the Angiogenesis Inhibitors market.

Restraints2 items

High development costs and the lengthy approval process for new Angiogenesis Inhibitors are significant restraints on the growth of the Angiogenesis Inhibitors market, impacting its overall growth forecast.

The presence of generic alternatives and patent expirations of existing Angiogenesis Inhibitors can limit the revenue growth of the Angiogenesis Inhibitors market size, making it essential for companies to develop new and innovative products.

Opportunities2 items

The growing demand for personalized medicine and targeted therapies presents opportunities for the development of novel Angiogenesis Inhibitors, driving growth in the Angiogenesis Inhibitors market and increasing its market size.

Increasing research collaborations and partnerships between pharmaceutical companies, research institutions, and biotechnology firms can accelerate the development of new Angiogenesis Inhibitors and contribute to the growth forecast of the Angiogenesis Inhibitors market.

Challenges2 items

The complexity of cancer biology and the heterogeneity of tumors pose significant challenges in the development of effective Angiogenesis Inhibitors, affecting the growth of the Angiogenesis Inhibitors market size and its growth forecast.

The need for stricter regulations and standardization of Angiogenesis Inhibitors can create challenges for companies operating in the Angiogenesis Inhibitors market, requiring them to adapt to changing regulatory environments and ensure compliance.

Market Segmentation

Loading chart…

The Application segment of the Angiogenesis Inhibitors market refers to the various therapeutic areas where these inhibitors are used. This includes cancer treatment, age-related macular degeneration, and rheumatoid arthritis. The application segment is a crucial part of the Angiogenesis Inhibitors segmentation, as it helps in understanding the demand for these inhibitors in different therapeutic areas. The cancer treatment segment is the largest application segment, accounting for the majority of the market share. This is due to the high prevalence of cancer and the increasing use of angiogenesis inhibitors in cancer treatment.

The Types segment of the Angiogenesis Inhibitors market includes monoclonal antibodies and tyrosine kinase inhibitors. Monoclonal antibodies, such as bevacizumab, are the most widely used type of angiogenesis inhibitors. Tyrosine kinase inhibitors, such as sunitinib, are also used to treat various types of cancer. Understanding the types of angiogenesis inhibitors is essential for Angiogenesis Inhibitors market taxonomy, as it helps in identifying the key players and their market share. The types segment is expected to grow significantly during the forecast period, driven by the increasing demand for effective cancer treatments.

Angiogenesis Inhibitors Segmentation Breakdown10 items

Application

Kidney Cancer

Lung Cancer

Breast Cancer

Colon Cancer

Other

Types

Oral

Injectable

Other

Regional Insights

Loading chart…

The Angiogenesis Inhibitors market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of angiogenesis inhibitors, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and significant investments in research and development. In Europe, drivers include favorable policies, a strong infrastructure, and a high level of adoption. Asia Pacific is driven by a large and growing demographics, increasing adoption, and significant investments in healthcare. Latin America and Middle East & Africa are expected to be driven by increasing adoption, improving infrastructure, and growing investments in healthcare.

The regional forecast indicates that the Angiogenesis Inhibitors market will continue to grow, driven by increasing demand for effective cancer treatments. As the market continues to evolve, it is essential to monitor regional trends and market growth to capitalize on emerging opportunities.

Competitive Landscape

The Angiogenesis Inhibitors market is moderately consolidated, with a mix of global players and local companies. The Angiogenesis Inhibitors competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players tend to dominate the market, but local companies are also gaining traction through strategic partnerships and localized product offerings.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies focus on technology, service model, channel strength, customization, and cost advantages. The following companies have adopted distinct strategic focuses:

Roche: regional expansion

Pfizer: innovation pipeline

Exelixis: premium pricing

Novartis: local manufacturing

Takeda Pharmaceutical: OEM tie-ups

Melinta Therapeutics: vertical integration

Key Angiogenesis Inhibitors Companies14 items

Roche

Pfizer

Exelixis

Novartis

Takeda Pharmaceutical

Melinta Therapeutics

Cipla

Sun Pharmaceutical Industries

Bristol-Myers Squibb

Balaji Medical Services

Eli Lilly

Bayer

Sanofi

Merck & Co

Market Ecosystem

The Angiogenesis Inhibitors ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value creation and capture occur through the development, manufacturing, and distribution of angiogenesis inhibitors, which are used to treat various diseases. The ecosystem's boundaries are defined by the interactions among these participants, influencing how value flows through the system.

Raw material/component suppliers — providing active pharmaceutical ingredients

OEMs / manufacturers — producing angiogenesis inhibitors

Technology providers — developing drug delivery systems

System integrators / EPCs — integrating inhibitors into treatment regimens

Distributors / channel partners — supplying inhibitors to healthcare providers

Regulators/standards bodies — overseeing safety and efficacy

End users / buyers — receiving treatment with angiogenesis inhibitors

In the Angiogenesis Inhibitors ecosystem, control points are largely influenced by regulators and standards bodies, as they oversee the approval and monitoring of these inhibitors. Dependency risks arise from input constraints, such as the availability of active pharmaceutical ingredients, and standards, including those related to manufacturing and safety. Switching costs and partnerships between participants can also impact the ecosystem, particularly in terms of interoperability requirements. A thorough value chain analysis is necessary to understand these dynamics and how they vary by region, given the diverse regulatory landscapes and healthcare systems in different areas.

Recent Industry Insights

The Angiogenesis Inhibitors industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between pharmaceutical companies to develop novel angiogenesis inhibitors, have been a key focus area. Additionally, there have been notable mergers and acquisitions, with companies looking to expand their portfolios and strengthen their market presence. The industry has also seen the launch of new products and technologies, including innovative drug delivery systems and combination therapies.

Furthermore, regulatory changes have had a profound impact on the Angiogenesis Inhibitors industry, with updated guidelines and approvals influencing the development and commercialization of these therapies. Shifts in consumer and enterprise trends have also been observed, with an increasing emphasis on personalized medicine and targeted therapies. Funding rounds and expansions have been secured by several companies, enabling them to advance their research and development programs and bring new treatments to market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Angiogenesis Inhibitors market outlook. The market attractiveness is moderate, driven by increasing demand for cancer treatments and a growing patient population. Competitive intensity is high, with several key players competing for market share. The long-term outlook is promising, with potential applications in ophthalmology and other diseases. The innovation landscape is rapidly evolving, with ongoing research and development of new inhibitors.

The demand-supply balance is expected to remain stable, with key risk factors including regulatory challenges and high development costs. Despite these risks, the Angiogenesis Inhibitors market outlook remains positive, with opportunities for growth and expansion into new therapeutic areas. Overall, my expert view is that the market will continue to grow, driven by increasing demand and ongoing innovation.

11 items

1. Executive Summary

2. Angiogenesis Inhibitors Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Angiogenesis Inhibitors Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Angiogenesis Inhibitors Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Kidney Cancer

6.1.2. Lung Cancer

6.1.3. Breast Cancer

6.1.4. Colon Cancer

6.1.5. Other

6.2. Global Angiogenesis Inhibitors Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Oral

6.2.2. Injectable

6.2.3. Other

6.3. Global Angiogenesis Inhibitors Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Angiogenesis Inhibitors Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Angiogenesis Inhibitors Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Angiogenesis Inhibitors Market Competition by Key Manufacturers

8.1. Global Angiogenesis Inhibitors Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Angiogenesis Inhibitors: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Roche

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Pfizer

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Exelixis

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Novartis

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Takeda Pharmaceutical

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Melinta Therapeutics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Cipla

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sun Pharmaceutical Industries

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Bristol-Myers Squibb

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Balaji Medical Services

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Eli Lilly

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Bayer

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Sanofi

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Merck & Co

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Angiogenesis Inhibitors Market

Figure 4: Global Angiogenesis Inhibitors Market: Drivers

Figure 5: Global Angiogenesis Inhibitors Market: Challenges

Figure 6: Global Angiogenesis Inhibitors Market: Trends

Figure 7: Global Angiogenesis Inhibitors Market: Opportunity

Figure 8: Global Angiogenesis Inhibitors Market: Restraint

Figure 9: Global Angiogenesis Inhibitors Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Angiogenesis Inhibitors Market Value (USD Million) By Region

Figure 15: Global Angiogenesis Inhibitors Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Angiogenesis Inhibitors Market Value (USD Million) By Region

Figure 23: Global Angiogenesis Inhibitors Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Angiogenesis Inhibitors Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Angiogenesis Inhibitors Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Angiogenesis Inhibitors Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Angiogenesis Inhibitors Market Value (USD Million) By Region

Table 10: Global Angiogenesis Inhibitors Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Angiogenesis Inhibitors Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Angiogenesis Inhibitors Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Angiogenesis Inhibitors Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Roche Basic Information And Sales Area

Table 31: Roche. Products Portfolio

Table 32: Pfizer Basic Information And Sales Area

Table 33: Pfizer. Products Portfolio

Table 34: Exelixis Basic Information And Sales Area

Table 35: Exelixis. Products Portfolio

Table 36: Novartis Basic Information And Sales Area

Table 37: Novartis. Products Portfolio

Table 38: Takeda Pharmaceutical Basic Information And Sales Area

Table 39: Takeda Pharmaceutical. Products Portfolio

Table 40: Melinta Therapeutics Basic Information And Sales Area

Table 41: Melinta Therapeutics. Products Portfolio

Table 42: Cipla Basic Information And Sales Area

Table 43: Cipla. Products Portfolio

Table 44: Sun Pharmaceutical Industries Basic Information And Sales Area

Table 45: Sun Pharmaceutical Industries. Products Portfolio

Table 46: Bristol-Myers Squibb Basic Information And Sales Area

Table 47: Bristol-Myers Squibb. Products Portfolio

Table 48: Balaji Medical Services Basic Information And Sales Area

Table 49: Balaji Medical Services. Products Portfolio

Table 50: Eli Lilly Basic Information And Sales Area

Table 51: Eli Lilly. Products Portfolio

Table 52: Bayer Basic Information And Sales Area

Table 53: Bayer. Products Portfolio

Table 54: Sanofi Basic Information And Sales Area

Table 55: Sanofi. Products Portfolio

Table 56: Merck & Co Basic Information And Sales Area

Table 57: Merck & Co. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Types

Table 61: Global Market Share (%) By Types (2032)

Table 62: Global Angiogenesis Inhibitors Market Value (USD Million) By Region

Table 63: Global Angiogenesis Inhibitors Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: North America Market Value (USD Million) (2025-2032) By Types

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Types

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Types

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Angiogenesis Inhibitors Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Pfizer; Exelixis; Novartis; Takeda Pharmaceutical; Melinta Therapeutics; Cipla; Sun Pharmaceutical Industries; Bristol-Myers Squibb; Balaji Medical Services; Eli Lilly; Bayer; Sanofi; Merck & Co
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options